Newly developed separation membrane device for the purification process of antibody drug manufacturing.
大塚化学
Otsuka Chemical Co., Ltd. has recently developed a new separation membrane device for the purification process in antibody drug manufacturing as a result of its alliance agreement with Toyobo Co., Ltd. By adopting this separation membrane device instead of the conventional column chromatography method, it is possible to reduce the number of steps in the purification process by one-fourth, contributing to increased productivity. Sample provision for pharmaceutical manufacturers and research institutions began at the end of April. Antibody drugs are pharmaceuticals that utilize antibodies with the property of binding to specific antigens. They can be designed to target and attack cells or molecules with antigens that cause diseases, offering high therapeutic effects and reduced side effects. The market is expected to expand at an annual rate of approximately 15% until 2030.
